Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics

Calliditas Therapeutics AB ADR (CALT): $18.36

0.61 (+3.44%)

POWR Rating

Component Grades














  • CALT scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.09% of US stocks.
  • The strongest trend for CALT is in Value, which has been heading up over the past 179 days.
  • CALT's current lowest rank is in the Quality metric (where it is better than 9.48% of US stocks).

CALT Stock Summary

  • The ratio of debt to operating expenses for Calliditas Therapeutics AB is higher than it is for about merely 0.5% of US stocks.
  • CALT's price/sales ratio is 10,382.75; that's higher than the P/S ratio of 99.91% of US stocks.
  • As for revenue growth, note that CALT's revenue has grown -99.16% over the past 12 months; that beats the revenue growth of only 0.69% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Calliditas Therapeutics AB, a group of peers worth examining would be MRSN, EQS, VHC, VNRX, and TFFP.
  • CALT's SEC filings can be seen here. And to visit Calliditas Therapeutics AB's official web site, go to

CALT Stock Price Chart Interactive Chart >

Price chart for CALT

CALT Price/Volume Stats

Current price $18.36 52-week high $33.19
Prev. close $17.75 52-week low $12.55
Day low $17.65 Volume 5,100
Day high $18.50 Avg. volume 15,854
50-day MA $16.98 Dividend yield N/A
200-day MA $19.37 Market Cap 480.50M

Calliditas Therapeutics AB ADR (CALT) Company Bio

Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

CALT Latest News Stream

Event/Time News Detail
Loading, please wait...

CALT Latest Social Stream

Loading social stream, please wait...

View Full CALT Social Stream

Latest CALT News From Around the Web

Below are the latest news stories about Calliditas Therapeutics AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.

Year-End Report, 2021

"The accelerated approval of TARPEYO was for the indication of reduction of proteinuria, which was the endpoint of Part A of the trial, in adult patients with IgA nephropathy with risk of rapid progression, which is characterized as generally UPCR ≥ 1.5 g/g. It is well established that patients with higher levels of proteinuria have a worse outlook and prognosis as they tend to experience a more rapid decline of their kidney function, as measured by eGFR. These patients are therefore at consider

Yahoo | February 24, 2022

First patient randomized in pivotal TRANSFORM study with setanaxib

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in the company's pivotal phase 2b/3 TRANSFORM study in patients with primary biliary cholangitis (PBC).

Yahoo | February 15, 2022

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the commercial availability and initial sales of TARPEYO™ (budesonide), the first and only FDA approved treatment for IgA nephropathy, indicated for reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally considered a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g. IgAN is a rare, progressive autoimmune disease, which has a high unmet

Yahoo | January 28, 2022

LifeSci Capital Releases a Buy Rating on Calliditas Therapeutics (CALT)

In a report issued on December 16, Rami Katkhuda from LifeSci Capital assigned a Buy rating to Calliditas Therapeutics (CALT – Research Report), with a price target of $56.00. The company's shares closed last Friday at $23.48. According to, Katkhuda is ranked #7318 out of 7739 analysts. Currently, the analyst consensus on Calliditas Therapeutics is a Strong Buy with an average price target of $54.33, representing a 137.6% upside. In a report issued on December 16, Stifel Nicolaus also maintained a Buy rating on the stock with a $55.00 price target. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $34.

Carrie Williams on TipRanks | December 20, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

William White on InvestorPlace | December 20, 2021

Read More 'CALT' Stories Here

CALT Price Returns

1-mo -4.21%
3-mo -6.56%
6-mo -23.63%
1-year -39.21%
3-year N/A
5-year N/A
YTD -25.85%
2021 -26.35%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5459 seconds.